Matches in Wikidata for { <http://www.wikidata.org/entity/Q91802262> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- Q91802262 description "2019 թվականի ապրիլի 11-ին հրատարակված գիտական հոդված" @default.
- Q91802262 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q91802262 description "scientific article published on 11 April 2019" @default.
- Q91802262 description "wetenschappelijk artikel" @default.
- Q91802262 description "наукова стаття, опублікована 11 квітня 2019" @default.
- Q91802262 name "Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome" @default.
- Q91802262 name "Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome" @default.
- Q91802262 type Item @default.
- Q91802262 label "Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome" @default.
- Q91802262 label "Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome" @default.
- Q91802262 prefLabel "Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome" @default.
- Q91802262 prefLabel "Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome" @default.
- Q91802262 P1433 Q91802262-714B4FC0-E7C9-4870-B7EC-83C60D76A6F1 @default.
- Q91802262 P1476 Q91802262-41ADDAE1-B964-4C10-B9FC-5026D49578A1 @default.
- Q91802262 P2093 Q91802262-044F51F7-A4BE-47B2-BFE9-EF60B3E43F33 @default.
- Q91802262 P2093 Q91802262-2406CCFC-200B-41FE-9280-B78C67B6358B @default.
- Q91802262 P2093 Q91802262-351D5387-90A2-452C-9F14-5A1356F0B724 @default.
- Q91802262 P2093 Q91802262-35AC1C57-B502-440F-95AD-2E6880CB1A2A @default.
- Q91802262 P2093 Q91802262-3B26D0EF-9953-4FBD-A6AF-4EC18966D6EF @default.
- Q91802262 P2093 Q91802262-6A7A131E-1DFC-400A-ADBA-5F7CF7207011 @default.
- Q91802262 P2093 Q91802262-83125B36-8015-41B8-8D9D-77F5E480F17C @default.
- Q91802262 P2093 Q91802262-8EA1D052-5B26-453B-A055-CD1CC8243CA3 @default.
- Q91802262 P2093 Q91802262-9F907DFE-5C08-4B21-9300-3C38CFCC99AB @default.
- Q91802262 P2093 Q91802262-AF8879CF-1F1C-49C3-ACD0-12879F5DE4EA @default.
- Q91802262 P2093 Q91802262-B69F840D-BC5F-4A4E-ABBC-208DBE374A4F @default.
- Q91802262 P2093 Q91802262-CFF96848-6768-45BD-A93A-CD8860EE300E @default.
- Q91802262 P2093 Q91802262-DB201C2C-E23E-440E-B516-3FB2344A0D24 @default.
- Q91802262 P2093 Q91802262-DB655E38-6F64-4906-93E8-E9B7958CFBAE @default.
- Q91802262 P2093 Q91802262-ECB48FB3-8C88-4C3A-952A-78C7BA563967 @default.
- Q91802262 P304 Q91802262-037F0CBB-32E6-4882-A872-24BB06DDC90E @default.
- Q91802262 P31 Q91802262-501F27B5-BA1D-4AA6-99BD-D6B540E344B0 @default.
- Q91802262 P356 Q91802262-A48E8A34-50E3-4E48-A6A0-067F1E1BD722 @default.
- Q91802262 P433 Q91802262-3676A0C9-9AB5-4D28-8BCB-80FF26089D5B @default.
- Q91802262 P478 Q91802262-95D190EF-342D-42DF-A97F-CEF6F3FA95FA @default.
- Q91802262 P50 Q91802262-F33C4F06-A0F8-404B-A3FD-CBB2916D3CA5 @default.
- Q91802262 P577 Q91802262-76BF2CC9-EA2B-4549-A9CB-8450308F3543 @default.
- Q91802262 P698 Q91802262-35F43B34-6D17-4824-83C0-BB9209FD445A @default.
- Q91802262 P921 Q91802262-67278754-4855-49DA-A2BC-D6C19A766079 @default.
- Q91802262 P356 J.CLML.2019.03.016 @default.
- Q91802262 P698 31060990 @default.
- Q91802262 P1433 Q5133774 @default.
- Q91802262 P1476 "Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome" @default.
- Q91802262 P2093 "Dong Won Baek" @default.
- Q91802262 P2093 "Gyeong-Won Lee" @default.
- Q91802262 P2093 "Ho Jin Shin" @default.
- Q91802262 P2093 "Ho Sup Lee" @default.
- Q91802262 P2093 "Hyeoung-Joon Kim" @default.
- Q91802262 P2093 "Jae-Sook Ahn" @default.
- Q91802262 P2093 "Joo Seop Chung" @default.
- Q91802262 P2093 "Joon Ho Moon" @default.
- Q91802262 P2093 "Sang Kyun Sohn" @default.
- Q91802262 P2093 "Sang Min Lee" @default.
- Q91802262 P2093 "Sung Nam Lim" @default.
- Q91802262 P2093 "Sungwoo Park" @default.
- Q91802262 P2093 "Won Sik Lee" @default.
- Q91802262 P2093 "Yoo Jin Lee" @default.
- Q91802262 P2093 "Yoon Young Cho" @default.
- Q91802262 P304 "e367-e373" @default.
- Q91802262 P31 Q13442814 @default.
- Q91802262 P356 "10.1016/J.CLML.2019.03.016" @default.
- Q91802262 P433 "7" @default.
- Q91802262 P478 "19" @default.
- Q91802262 P50 Q87433063 @default.
- Q91802262 P577 "2019-04-11T00:00:00Z" @default.
- Q91802262 P698 "31060990" @default.
- Q91802262 P921 Q954625 @default.